Security Snapshot

MYRIAD GENETICS INC - Common Stock (MYGN) Institutional Ownership

CUSIP: 62855J104

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

194

Shares (Excl. Options)

88,959,231

Price

$5.71

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+928,872
Value change
+$19,572,949
Number of holders
194
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
95,201,317
SEC-reported price per share
$3.17
Insider filing price
$3.17
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • MYGN - MYRIAD GENETICS INC - Common Stock is tracked under CUSIP 62855J104.
  • 194 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 202 to 194 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $396,366,870 to $507,800,824.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 194 institutions filings for Q2 2026.

Open SEC evidence

Security key

62855J104

Latest holder period

Q2 2026

13F holders

194

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
MYGN
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock Portfolio Management LLC 10% $31,385,970 9,900,937 BlackRock Portfolio Management LLC 31 Aug 2026
BlackRock, Inc. 8.5% -45% $35,894,329 -$27,581,033 7,976,163 -43% BlackRock, Inc. 31 Mar 2026
INTEGRATED CORE STRATEGIES (US) LLC 7.2% +42% $41,205,972 +$12,003,761 6,700,158 +41% Millennium Management LLC 31 Dec 2025
Vestal Point Capital, LP 6.1% $33,607,100 5,735,000 Vestal Point Capital, LP 30 Jun 2026
STATE STREET CORP 5.3% +12% $29,212,452 +$3,287,653 4,985,060 +13% STATE STREET CORPORATION 30 Jun 2026
BARCLAYS PLC 4.2% -22% $28,480,691 -$6,945,955 3,939,238 -20% Barclays PLC 30 Sep 2025
Camber Capital Management LP 3.4% $22,320,000 3,100,000 Camber Capital Management LP 31 Dec 2024
DISCIPLINED GROWTH INVESTORS INC /MN 0.8% -86% $4,244,772 -$19,924,683 753,956 -82% DISCIPLINED GROWTH INVESTORS INC /MN 30 Jun 2025

As of 30 Jun 2026, 194 institutional investors reported holding 88,959,231 shares of MYRIAD GENETICS INC - Common Stock (MYGN). This represents 93% of the company’s total 95,201,317 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
76%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 10,890,440 +23% 0% $62,184,412
MILLENNIUM MANAGEMENT LLC 7% 6,620,372 -0.73% 0.03% $37,802,324
Vestal Point Capital, LP 6% 5,735,000 +248% 0.77% $32,746,850
STATE STREET CORP 5.2% 4,985,060 +13% 0% $28,464,693
D. E. Shaw & Co., Inc. 4.8% 4,582,083 +1.8% 0.02% $26,163,694
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 4,081,376 +4% 0% $23,304,657
ACADIAN ASSET MANAGEMENT LLC 3.3% 3,126,973 +35% 0.02% $17,840,000
VANGUARD PORTFOLIO MANAGEMENT LLC 3.2% 3,079,670 +19% 0% $17,584,916
AQR CAPITAL MANAGEMENT LLC 2.9% 2,766,689 +45% 0.01% $15,797,792
MORGAN STANLEY 2.6% 2,481,104 -22% 0% $14,167,103
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,416,197 +4.2% 0% $13,800,073
GOLDMAN SACHS GROUP INC 2.2% 2,056,843 -13% 0% $11,744,574
JACOBS LEVY EQUITY MANAGEMENT, INC 2% 1,891,527 -9.4% 0.04% $10,800,619
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.8% 1,740,794 -3.4% 0% $9,939,934
Qube Research & Technologies Ltd 1.7% 1,665,835 -1.5% 0.01% $9,511,918
FEDERATED HERMES, INC. 1.6% 1,570,314 -21% 0.01% $8,966,493
TWO SIGMA INVESTMENTS, LP 1.6% 1,557,727 +21% 0.01% $8,894,621
Nuveen, LLC 1.6% 1,545,549 +68% 0% $8,825,085
MACKENZIE FINANCIAL CORP 1.6% 1,535,702 0.01% $8,768,858
CITADEL ADVISORS LLC 1.6% 1,533,684 +239% 0.01% $8,757,335
Connor, Clark & Lunn Investment Management Ltd. 1.5% 1,407,860 +6.8% 0.02% $8,038,880
Aberdeen Group plc 1.4% 1,308,933 +18% 0.01% $7,474,007
MARSHALL WACE, LLP 1.3% 1,222,804 +11% 0.01% $6,982,210
DIMENSIONAL FUND ADVISORS LP 1.1% 1,051,996 +42% 0% $6,008,336
Assenagon Asset Management S.A. 1.1% 1,031,464 -29% 0.01% $5,889,659

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 88,959,231 $507,800,824 +$19,572,949 $5.71 194
2026 Q1 88,065,250 $396,366,870 -$20,933,860 $4.50 202
2025 Q4 92,194,007 $567,141,060 +$27,455,645 $6.15 220
2025 Q3 88,492,355 $639,685,484 +$7,333,020 $7.23 215
2025 Q2 90,529,530 $480,755,771 -$73,903,588 $5.31 216
2025 Q1 93,969,029 $833,362,943 +$10,158,296 $8.87 226
2024 Q4 92,375,178 $1,266,992,283 -$38,609,730 $13.71 215
2024 Q3 90,691,605 $2,483,201,789 -$46,730,979 $27.39 242
2024 Q2 92,267,243 $2,256,709,187 -$39,028,941 $24.46 222
2024 Q1 93,842,572 $2,001,184,496 +$85,643,654 $21.32 185
2023 Q4 89,898,458 $1,720,778,542 +$139,092,939 $19.14 193
2023 Q3 82,696,930 $1,326,499,466 +$18,782,858 $16.04 184
2023 Q2 81,069,882 $1,879,159,822 -$25,379,016 $23.18 184
2023 Q1 82,216,167 $1,909,846,418 +$45,174,636 $23.23 186
2022 Q4 80,553,035 $1,168,812,560 -$19,067,888 $14.51 191
2022 Q3 81,539,353 $1,555,961,809 +$26,155,420 $19.08 184
2022 Q2 79,888,231 $1,451,741,809 +$19,085,207 $18.17 185
2022 Q1 78,868,034 $1,987,215,536 +$13,382,979 $25.20 198
2021 Q4 78,283,503 $2,159,672,726 -$41,784,396 $27.60 191
2021 Q3 79,271,409 $2,560,639,030 +$122,124,573 $32.29 208
2021 Q2 75,479,842 $2,308,615,173 +$49,345,949 $30.58 198
2021 Q1 73,860,328 $2,248,603,947 -$35,142,715 $30.45 193
2020 Q4 74,996,999 $1,483,013,849 +$38,048,718 $19.78 176
2020 Q3 78,424,909 $1,022,586,628 +$19,999,510 $13.04 185
2020 Q2 72,886,989 $826,507,154 -$36,910,370 $11.34 188
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .